Perspectives
Cell therapy growing quickly and serving rare conditions
FDA has approved a diverse group of cell and tissue therapies
May 9, 2023What is cell therapy?
Cell therapy involves the intravenous transfer of intact or biologically modified live cells or tissues to a patient. Cell therapy may prevent, treat, cure, diagnosis or mitigate rare cancers, diseases or injuries. It does so without altering the underlying genetic condition. The cells are cultivated or modified outside of the body before being injected into the patient. Cell therapy restores or alters certain sets of cells, or uses cells to carry a therapy throughout the body.1,2,3 Cells or tissues used in cell-based therapies may be obtained from the patient’s own cells or tissues (autologous) or from a donor (allogeneic).
CAR-T therapy, or chimeric antigen receptor T cell therapy, uses the technologies of both gene therapy and cell therapy. For Prime’s purposes, we define CAR-T as cell therapy, not gene therapy.
What is gene therapy? What’s the difference?
Gene therapy involves the transfer of genetic material, usually in a carrier or vector, and the uptake of the gene into the appropriate cells of the body. Cell therapy involves the transfer of cells with the relevant function into the patient. Some protocols use both gene therapy and cell therapy.
Cells are the basic building blocks of all living things; genes can be found deep within cells. Genes are small sections of DNA that carry genetic information and instructions for making proteins, which help build and maintain the body.1,2,3
Cell therapies on the market as of February 2023
There are seven cell therapy products FDA-approved to date. (See “What is gene therapy?” for a list of gene therapy products.)
An estimated five to 10 cell therapies have PDUFA dates in 2023.
FDA Approved CAR T-Cell Therapy One-Time Administration or One-Time Administration Tissue-Based Therapy with WAC of > $399,000
Name | Manufacturer | Indication | WAC |
Approval Date* |
Kymriah™ (tisagenlecleucel) | Novartis |
Pediatric ALL & LBCL & FL |
$508,250 $399,110 |
August 2017 |
Yescarta™ (axicabtagene ciloleucel) |
Kite | LBCL & FL | $399,000 | October 2017 |
Tecartus™ (brexucabtagene autoleucel) |
Kite | Mantle cell lymphoma | $399,000 | July 2020 |
Breyanzi™ (lisocabtagene maraleucel) |
BMS | LBCL | $410,300 | February 2021 |
Abecma™ (idecabtagene vicleucel) |
BMS and bluebird bio | Multiple myeloma | $419,500 | March 2021 |
Rethymic™ (allogeneic processed thymus tissue agdc) | Enzyvant | Congenital athymia | ~$2.7 million | October 2021 |
Carvykti™ (ciltacabtagene autoleucel) |
Janssen | Relapsed and refractory multiple myeloma | $465,000 | February 2022 |
* Anticipated approval dates are predictions made by Prime Therapeutics, based on industry information.
References
- https://www.genemedi.net/i/ex-vivo-in-vivo-in-vitro
- https://asgct.org/education/more-resources/gene-and-cell-therapy-faqs#:~:text=Gene%20therapy%20involves%20the%20transfer,gene%20therapy%20and%20cell%20therapy.
- https://www.novartis.com/about/innovative-medicines/novartis-pharmaceuticals/novartis-gene-therapies/what-cell-and-gene-therapy#:~:text=Cells%20are%20the%20basic%20building,and%20maintain%20the%20body1.
Related news
Perspectives
June 8, 2023
July 2023 decisions expected from the FDA
At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…
Perspectives
June 8, 2023
HR to HX: Creating Moments that Matter
Prime Therapeutics’ (Prime) Senior Vice President and Chief Human Resources Officer (CHRO), Erin…
Perspectives
June 5, 2023
Oncology Update: Advances in Breast Cancer Management
New approvals and a broad pipeline promise advances in the treatment of breast…